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Abstract
Background: Previous investigations on the association of human papillomavirus (HPV) and human bladder cancer
have led to conflicting results. The aim of this study was to determine if low and high risk HPV play a role in the
etiology of superficial low grade and invasive high grade urothelial carcinoma of the bladder.
Methods: We prospectively collected tumor samples of urothelial carcinoma of the bladder from 109 patients
treated with transurethral resection or cystectomy, with bladder tissue from transurethral resection of the prostate
serving as control. Unfixed, frozen tumor samples were analyzed for the presence of 14 high risk HPV types using
real time PCR. Additionally, all specimens were tested for 35 low risk HPV types with a conventional PCR using
degenerate primers located in the L1 region. Six frozen samples of cervical carcinoma served as positive controls.
Results: We included 109 cases of bladder cancer with 41 superficial (pTa low grade) tumors, 56 invasive
(pT1-T4) high grade tumors and 12 others (pTa high grade + pTis). We have not detected HPV-DNA in any
sample (95 % Confidence Interval [CI] 0–3.3 %), superficial tumors (95 % CI 0–6.4 %) or in invasive tumors
(95 % CI 0–8.6 %) with correct positive controls.
Conclusions: Using a broad, sensitive assay with prospectively collected specimens of a Central European population
we could not detect HPV-DNA in any of the cases. Our results suggest that it is unlikely that HPV infections play
a major role in the development of urothelial bladder cancer.
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Introduction
Bladder cancer is the fourth most common malignancy
of males and the eighth most common of females and
leads to estimated 170,000 deaths per year worldwide
[1]. Bladder cancer shows urothelial differentiation in
more than 90 % of cases in Western countries. It can be
separated into two major entities. On the one hand there
are superficial, low grade (G1) tumors, which are rela-
tively benign but do often recur, on the other hand there
are invasive, high grade (G3) tumors, which have a high
risk of progression, metastasis and cancer-related death.
Several risk factors have been identified like tobacco
use as well as occupational or environmental exposure
to noxious substances like aromatic amines [2]. So far,
prevention strategies are limited to the elimination of
risk factors while treatment of bladder cancer is invasive
and intensive in terms of costs and time [3]. Addition-
ally, treatment is further hindered by the lack of good
markers for prognosis and therapy response [4]. The
WHO estimated that about 12 % of worldwide cancer
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cases are caused by viral infections [5]. Thus, identifica-
tion of an infectious agent like human papilloma virus
(HPV) in the etiology of bladder cancer might have a
relevant impact on prevention and therapy. HPV is a
DNA virus which belongs to the papillomavirus family.
It has been shown that HPV plays a crucial role in the
development of cervical carcinoma [6] and is also
linked to anal, vaginal, penile and oropharyngeal tu-
mors. HPV is a highly-divergent virus with more than
150 types, which are grouped into high risk and low
risk according to their potential to induce malignant
transformation [7].
It is known for cattle that the infection with bovine
papillomavirus (BPV) in combination with certain food
components leads to bladder cancer [8]. On the con-
trary, the role of HPV in human bladder cancer is un-
clear. Published studies show inconsistent results
concerning HPV association in bladder cancer, with a
prevalence from 0 % [9–12] to 35–52 % [13–15]. This
might be due to low case numbers, diversity of patients
and analyzed tumor entities and restriction of the ana-
lysis to a subset of HPV types. Another issue is potential
contamination, leading to false positive results, which
can for example occur during the cutting process of for-
malin fixed, paraffin-embedded tissue, sample prepar-
ation or DNA analysis.
We aimed at clarifying the role of HPV in the etiology
of urothelial cancer and therefore conducted a system-
atic study analyzing sufficient case numbers and care-
fully controlling logistic and technical biases (see Fig. 1).
To this end, we analyzed the presence of HPV-DNA in
superficial low grade and invasive high grade urothelial
cancer. We used highly sensitive PCRs to detect a broad




The study was performed in a prospective manner. A
complete study protocol was written before start of the
study. The study was approved by the ethics commission
of the faculty of medicine of Technische Universität
München before start of enrollment. All patients signed
a written informed consent prior to study entry.
Patients undergoing cystectomy or transurethral resec-
tion of the bladder (TURB) at the Department of Urology,
University Hospital rechts der Isar of the Technische
Universität München, were enrolled. Only patients with
histologically confirmed urothelial carcinoma of the
bladder were included and classified according to TNM-
system (UICC 2010). Patients with benign prostate
hyperplasia served as controls, who underwent trans-
urethral resection of the prostate (TURP) at the same
hospital and had no history of urologic neoplasia. We
chose this patient group for two reasons: First, TURP is
performed for a non-neoplastic condition. Second, it is
possible to get bladder mucosa samples during the ne-
cessary operation, whereas surgery in healthy controls
for study reasons only is ethically not justifiable.
Tissue samples of bladder cancer were collected during
cystectomy or TURB. Samples were dissected under ster-
ile conditions and immediately transferred to RNAlater
Fig. 1 Flow chart describing study design and enrollment. Because of the negative result in the screening phase, planned sequencing
and transcription analysis of positive cases could not be performed
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solution (Qiagen, Germany) and stored at −80 °C until
further processed for the extraction of nucleic acids. Of
each sample, a formalin-fixed part was used for histo-
logical analysis to confirm malignancy. Samples of nor-
mal bladder mucosa were obtained during TURP and
handled in the same way as the tumor samples, as well
as six samples of cervical carcinoma which served as
positive controls for the validation of extraction and de-
tection methods.
DNA Extraction
Tissue samples of 3×3 mm in size were homogenized in
700 μl lysis buffer using the Qiagen TissueLyser. DNA
was extracted with the Abbott m2000sp instrument in
500 μl sample volume and 70 μl eluate volume accord-
ing to the manufacture’s protocol. Positive and negative
control samples were extracted in the same run. For
positive control samples we used HPV positive tissue
from fresh frozen cervical carcinoma to control overall
sample handling, DNA extraction from tissue samples
and HPV detection. Cloned mouse prion protein gene
was added to each sample to control extraction efficiency.
PCR
HPV-DNA was detected by PCR amplification. For high
risk HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
58, 59, 66, 68) we used the Abbott Realtime HR HPV
assay using fluorescent probes and running on the
m2000sp instrument (Abbott, Wiesbaden, Germany).
Three forward and two reverse primers target the con-
served L1 region. According to the manufacturer, the
analytical sensitivity depends on the subtype: 500 copies
per assay for 16, 18, 35, 39, 45, 51, 59, 66, 68; 2000 cop-
ies per assay for 31, 33, 52, 56; and 5000 copies per assay
for 58. HPV-DNA positive solutions as well as SiHa cells
(kindly provided by Dr. S. Silling of the “Nationales
Referenzzentrum für Papillom- und Polyomaviren”,
Köln, Germany) harbouring 1–2 HPV copies per cell
were used as controls for analytical sensitivity. The en-
dogenous human beta globin gene (amplicon size 136
nucleotides) served as a control for cell adequacy, sam-
ple extraction and amplification efficiency.
Additionally we designed a nested conventional PCR for
broad detection of low risk HPV. To this end, nucleotide
sequences of 35 low risk HPV genotypes (6, 7, 11, 13, 30,
32, 34, 40, 42, 43, 44, 53, 54, 55, 57, 61, 62, 67, 69, 70, 72,
73, 74 81, 82, 83, 84, 85, 86, 87, 90, 91, 97, 102, 106) were
obtained from NCBI and were aligned with DNAMAN
(Lynnon Corporation, Canada). Sequences in the L1 re-
gion showing high homologies were selected for primer
design, leading to an amplicon of about 387 (380–390)
nucleotides in length. Ten forward primers and three re-
verse primers were designed to be highly specific for se-
lected HPV types. Inosine was used as a degenerate base
at up to two positions, tolerating up to one mismatch
(Table 1). We chose primers with similar melting temper-
atures and with low primer hybridization, self-annealing
and mispriming according to DNAMAN.
For validation of our in-house PCR, HPV-DNA iso-
lated from patient swabs positive for types 42, 53, 55, 44,
57, 61, 40 and 30, 33 were PCR amplified, cloned and se-
quenced. As standards we used plasmids with inserted
type 42 and 57 sequences. After TOPO cloning and
propagation in E. coli plasmid preparations were quanti-
fied and copy numbers were determined based on op-
tical density and molecular weight. Analytical sensitivity
was determined to be below 100 copies per reaction.
The PCR mix contained 5 μl of DNA samples, 1× reac-
tion buffer, 0.3 Taq polymerase (Qiagen), 20 pmol of
each primer (2 μl of 10 μM), 10 nmol of dNTP (2 μl of
5 mM) and water to a final volume of 50 μl. A median
amount of 109 ng DNA was added into each PCR reac-
tion. PCR conditions were the following: initially 1 acti-
vation cycle at 94 °C for 15 min, 45 cycles of
denaturation at 95 °C for 30 s, annealing at 46 °C for
30 s, elongation at 72 °C for 30 s, and a final elongation
cycle at 72 °C for 7 min. Amplification products were vi-
sualized under UV-light after electrophoresis in a 1.5 %
agarose gel, and amplicons of the correct size were
cloned and genotyped by sequencing.
Statistical planning and analysis was performed using R
Software (www.r-project.org) using continuity-corrected
confidence intervals for the difference between two inde-
pendent proportions [16].
Results
Our study included 109 patients with a median age of
73 years (range 45–94), 81 % were male. Five patients
Table 1 Primers used in the multiplex PCR for 35 low-risk HPV
types using IUPAC 1-letter code with I for desoxyinosines as
degenerate bases
Primer Sequence
Forward A 5'-AGG ATG GIG ACA TGG TGG A-3'
Forward B 5'-AGG ATG GTG ACA TGG TAG A-3'
Forward C 5'-AGG ATG GCG ACA TGG TTG A-3'
Forward D 5'-AGG ATG GGG ACA TGA TAG A-3'
Forward E 5'-AGG ATG GGG ACA TGA TTG A-3'
Forward F 5'-AGG ATG GIG ATA TGG TGG A-3'
Forward G 5'-AGG ATG GIG ATA TGG TAG A-3'
Forward H 5'- AGG ATG GIG ATA TGG TTG A-3'
Forward I 5'-AGG ATG GIG ATA TGA TAG A-3'
Forward J 5'-AGG ATG GIG ATA TGA TTG A-3'
Reverse A 5'-CAG GGI CAI AAC AAT GG-3'
Reverse B 5'-CAG GGI CAI AAT AAT GG-3'
Reverse C 5'- CAA GGI CAC AAT AAT GG-3'
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had been excluded due to non-urothelial cancer in the
final pathology assessment. Of the 109 cases with urothe-
lial cancer, 41 had superficial (pTa low grade) urothelial
cancer, 56 invasive (pT1-T4) high grade urothelial can-
cer and 12 other urothelial tumor types (pTa high grade
or pTis) (see Table 2).
Fresh tissue samples obtained during tumor resection
or TURP in control patients were subjected to DNA ex-
traction and PCR analysis for HPV. For high risk HPV
screening, we used the commercial Abbott test detecting
the following genotypes: 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66, 68. In order to detect a wide range of low
risk HPV genotypes, we developed a broad multiplex PCR
detecting at least the following 35 mucosa-associated
HPV genotypes: 6, 7, 11, 13, 30, 32, 34, 40, 42, 43, 44, 53,
54, 55, 57, 61, 62, 67, 69, 70, 72, 73, 74 81, 82, 83, 84, 85,
86, 87, 90, 91, 97, 102, 106 at high sensitivity.
We detected no HPV-DNA in any urothelial cancer
sample (95 % confidence Interval [CI] 0–3.3 %), super-
ficial tumors (95 % CI 0–6.4 %) or invasive tumors
(95 % CI 0–8.6 %) although for each run positive con-
trols were detected (sensitivity ≤100 copies). All urothe-
lial tissues from the control group of patients with
benign prostate hyperplasia (n = 26) were negative for
HPV-DNA. The respective 95 % continuity corrected
confidence intervals for the difference in proportions
(cases – controls) were −16.0 to +4.3 %, −16 to +8.0 %
and −16.0 to +10.7 %, the negative values correspond-
ing to the expectable difference in the prevalence of
HPV in the control group (TURP). Five of six cervical
carcinoma tissues were positive for high risk HPV.
SiHa cells harbor only 1–2 copies of HPV16 per cell.
Thus we used them to confirm the sensitivity of our test
procedure. DNA of approximately 5×106 cells was ex-
tracted with DNA Mini Kit (Qiagen, Germany) and eluted
in 200 μl, equaling 25,000 cells per μl. An in house PCR
detecting human prion protein to estimate the genomic
DNA content of a sample yielded an equivalent of 32,000
cells per μl. We then tested a serial dilution, starting with
1:10 and an input of 5 μl (corresponding to 105 cells). We
detected HPV 16 DNA down to 10 cells per assay
(1:10.000), corresponding to 10–20 HPV copies per assay.
This is approximately 1/1000 of the cell number which we
analyzed in our clinical samples. In conclusion our
method is able to detect HPV with a high sensitivity also
in cells with low copy numbers (1–2 copies per cell). With
a DNA amount equaling a cell count of >10,000 cells per
assay, both our in-house as well as the commercial Abbott
assay were able to detect ≤1 HPV copies per cell.
Discussion
In this study we analyzed two pathological subgroups of
bladder cancer for the presence of various high and low
risk HPV subtypes. Superficial low grade and invasive
high grade bladder cancer show very distinct characteris-
tics in regard to molecular alterations (like FGFR3 or
TP53 mutations) and clinical behavior and might repre-
sent different etiologic entities [17]. In our population
we detected no HPV-DNA in bladder tissue, irrespective
of subgroup, tumor stage or grade. Previous studies
mostly focused on high risk HPV as these have been
shown to cause malignant transformation due to the
oncogenic nature of their E6 and E7 proteins. However,
occasionally low risk HPV types were found in cancer-
ous lesions [18], and the classification in high and low
risk based on cervical cancer may not fit to all tissues.
Thus we also tested for a series of low risk HPV types
that are associated with mucosal infection. However, all
samples tested negative for all HPV types. Five of six
cervical cancer samples tested positive for HPV-DNA,
confirming that our extraction method worked properly.
By collecting all tissue samples prospectively and pro-
cessing only frozen, unfixed samples, we on the one
hand ensure high PCR sensitivity and on the other hand
avoid methods prone to contamination like processing
of formalin-fixed, paraffin-embedded material which
might be contaminated during cutting and storage of
samples. A potential limitation of our study remains the
case number, which makes it unlikely, but does not allow
to completely exclude HPV infections as a contributing
factor to bladder cancer. As expected, urothelial differ-
entiation was most common, limiting our conclusions to
this subtype. Also, no patients below the age of 45 years
Table 2 Patient characteristics
Patient characteristics
Age (years) Median Range
Case group 73 45-94
Control group 68 53-86
Male Female Overall
Case group 88 (81 %) 21 (19 %) 109
Control group 26 (100 %) 26
Histopathologic results (Case group) Male Female Overall
Low grade (G1)
pTa low grade 34 7 41 (38 %)
High grade (G3)
pTa/pTis 10 2 12 (11 %)
pT1 9 3 12 (11 %)
pT2 11 4 15 (14 %)
pT3 17 4 21 (19 %)
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were included in our group. With our methods we can-
not rule out that HPV plays a role at very early cancer
stages, for example with a “hit and run mechanism” as
discussed by Iwasaka et al. [19]. For instance HPV could
inactivate the p53 tumor suppressor gene years before
tumors occur and may be undetectable at the later
stages. However, HPV DNA is usually detectable in tu-
mors where it is thought to play a role in oncogenesis
[20]. Also the fact that we detected no HPV DNA in
early and advanced tumor stages argue against a role of
HPV in early carcinogenesis and subsequently disappear-
ing virus. Along these lines Pichler et al. found a very
low HPV prevalence in 186 retrospectively tested non-
muscle invasive bladder cancer tissues [21].
Two recent meta-analyses tried to elucidate the role
of HPV infection in bladder cancer [22, 23]. The au-
thors analyzed 22 case–control studies. The majority of
these included a small case number (n < 50) and a
mixed methodology. They reported an overall preva-
lence of 16.9 % (95 % CI: 14.4–17.4) and a pooled odds
ratio of 2.13 % (95 % CI: 1.54–2.95) resp. 2.84 % (95 %
CI: 1.39–5.8) for the presence of HPV in bladder cancer
tissue. The geographical distribution showed the high-
est prevalence in Asia (24.6 %), followed by Africa
(19.4 %) followed by North America (13.5 %) and Europe
(13.1 %) [23]. Both meta-analyses concluded that there
is a significant but moderate association between HPV
prevalence and bladder cancer. Our results do not sup-
port this conclusion, in line with results from Knowles
et al. [11] and Yavuzer et al. [24]. Knowles et al. ana-
lyzed 100 urothelial carcinomas by southern blot and a
general primer PCR for HPV-DNA in the 1990s in
Great Britain with negative result. Yavuzer et al. tested
70 cases of urothelial carcinoma with a nested PCR in
2011 in Turkey. No HPV-DNA was found in the
urothelial carcinomas, while 15/18 cervical carcinomas,
serving as positive controls were positive. As the meta-
analysis did neither take viral load nor PCR specificity
into account, positive association could have been ei-
ther caused by low PCR signals with unknown rele-
vance or by false-positive signals.
Detection of genomic DNA, particularly in low copy
numbers, shows no causal cancer relationship [25]. To
confirm positivity for HPV it would have been important
to analyze transcription and translation of HPV genes in
PCR positive samples. Functional analysis, e.g. studying
the interaction of HPV proteins with host pathways, can
proof oncogenicity in relevant cell types. However, de-
tection of HPV-DNA - as we did in our study - is still
regarded the most sensitive method of detection in
tumor samples.
We conclude that the absence of HPV DNA in normal
bladder and tumor tissue makes a strong association of
HPV with bladder cancer unlikely.
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